PLIANT THERAPEUTICS, INC. Comprehensive Income
PLIANT THERAPEUTICS, INC. (PLRX) reported Comprehensive Income of -$22.43 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$22.43M.
- PLIANT THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$20.37M.
- PLIANT THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$23.63M.
- PLIANT THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$26.27M.
- PLIANT THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$149.68M.
- PLIANT THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$210.33M.
- PLIANT THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$159.03M.
- PLIANT THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$125.08M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.43M 10-Q · filed 2026-08-11 | -$42.79M 10-Q · filed 2026-08-11 | -$66.42M derived: sum of 3 quarters · filed 2026-08-11 | -$92.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$20.37M 10-Q · filed 2026-05-11 | -$43.99M derived: sum of 2 quarters · filed 2026-05-11 | -$70.26M derived: sum of 3 quarters · filed 2026-05-11 | -$113.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$23.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$49.89M derived: sum of 2 quarters · filed 2026-03-11 | -$93.35M derived: sum of 3 quarters · filed 2026-08-11 | -$149.68M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$26.27M 10-Q · filed 2025-11-06 | -$69.73M derived: sum of 2 quarters · filed 2026-08-11 | -$126.05M 10-Q · filed 2025-11-06 | -$176.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$43.46M 10-Q · filed 2026-08-11 | -$99.79M 10-Q · filed 2026-08-11 | -$150.05M derived: sum of 3 quarters · filed 2026-08-11 | -$206.34M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$56.33M 10-Q · filed 2026-05-11 | -$106.59M derived: sum of 2 quarters · filed 2026-05-11 | -$162.88M derived: sum of 3 quarters · filed 2026-05-11 | -$218.87M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$50.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$106.56M derived: sum of 2 quarters · filed 2026-03-11 | -$162.54M derived: sum of 3 quarters · filed 2026-03-11 | -$210.33M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$56.30M 10-Q · filed 2025-11-06 | -$112.28M derived: sum of 2 quarters · filed 2025-11-06 | -$160.07M 10-Q · filed 2025-11-06 | -$198.93M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$55.98M 10-Q · filed 2025-08-07 | -$103.77M 10-Q · filed 2025-08-07 | -$142.63M derived: sum of 3 quarters · filed 2025-08-07 | -$183.78M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$47.79M 10-Q · filed 2025-05-08 | -$86.65M derived: sum of 2 quarters · filed 2025-05-08 | -$127.80M derived: sum of 3 quarters · filed 2025-05-08 | -$169.90M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$38.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$80.01M derived: sum of 2 quarters · filed 2025-03-03 | -$122.11M derived: sum of 3 quarters · filed 2025-03-03 | -$159.03M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$41.15M 10-Q · filed 2024-11-07 | -$83.25M derived: sum of 2 quarters · filed 2024-11-07 | -$120.18M 10-Q · filed 2024-11-07 | -$154.74M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$42.10M 10-Q · filed 2024-08-07 | -$79.02M 10-Q · filed 2024-08-07 | -$113.59M derived: sum of 3 quarters · filed 2025-03-03 | -$145.40M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$36.92M 10-Q · filed 2024-05-06 | -$71.48M derived: sum of 2 quarters · filed 2025-03-03 | -$103.30M derived: sum of 3 quarters · filed 2025-03-03 | -$133.15M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$34.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$66.37M derived: sum of 2 quarters · filed 2025-03-03 | -$96.23M derived: sum of 3 quarters · filed 2025-03-03 | -$125.08M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$31.81M 10-Q · filed 2023-11-09 | -$61.66M derived: sum of 2 quarters · filed 2023-11-09 | -$90.51M 10-Q · filed 2023-11-09 | -$115.21M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$29.86M 10-Q · filed 2023-08-09 | -$58.70M 10-Q · filed 2023-08-09 | -$83.40M derived: sum of 3 quarters · filed 2024-02-27 | -$110.45M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$28.85M 10-Q · filed 2023-05-09 | -$53.54M derived: sum of 2 quarters · filed 2024-02-27 | -$80.60M derived: sum of 3 quarters · filed 2024-02-27 | -$103.44M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$24.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$51.75M derived: sum of 2 quarters · filed 2024-02-27 | -$74.59M derived: sum of 3 quarters · filed 2024-02-27 | -$97.43M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$27.05M 10-Q · filed 2022-11-08 | -$49.90M derived: sum of 2 quarters · filed 2022-11-08 | -$72.74M 10-Q · filed 2022-11-08 | -$91.78M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$22.84M 10-Q · filed 2022-08-08 | -$45.69M 10-Q · filed 2022-08-08 | -$64.73M derived: sum of 3 quarters · filed 2022-08-08 | -$81.25M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$22.84M 10-Q · filed 2022-05-09 | -$41.88M derived: sum of 2 quarters · filed 2022-05-09 | -$58.41M derived: sum of 3 quarters · filed 2022-05-09 | -$75.50M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$19.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$35.56M derived: sum of 2 quarters · filed 2022-03-01 | -$52.65M derived: sum of 3 quarters · filed 2022-03-01 | -$41.56M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$16.52M 10-Q · filed 2021-11-09 | -$33.61M derived: sum of 2 quarters · filed 2021-11-09 | -$22.52M 10-Q · filed 2021-11-09 | $19.64M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$17.09M 10-Q · filed 2021-08-09 | -$6.00M 10-Q · filed 2021-08-09 | $36.17M derived: sum of 3 quarters · filed 2022-03-01 | $22.90M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $11.09M 10-Q · filed 2021-05-10 | $53.26M derived: sum of 2 quarters · filed 2022-03-01 | $39.99M derived: sum of 3 quarters · filed 2022-03-01 | $24.48M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $42.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $28.90M derived: sum of 2 quarters · filed 2022-03-01 | $13.39M derived: sum of 3 quarters · filed 2022-03-01 | -$632.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | -$13.27M 10-Q · filed 2020-11-10 | -$28.78M derived: sum of 2 quarters · filed 2020-11-10 | -$42.80M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$15.51M 10-Q · filed 2020-08-11 | -$29.53M 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |